Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects.
Chackalamannil
Samuel
S
Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA. samuel. chackalamannil@spcorp.com
D000470:Alkaloids / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000925:Anticoagulants / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D050197:Atherosclerosis / Q000188:drug therapy; D023903:Coronary Restenosis / Q000188:drug therapy; D005343:Fibrinolytic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D005663:Furans / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009281:Naphthalenes / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D010455:Peptides / Q000737:chemistry; D010880:Piperidines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use
D000470:Alkaloids; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D005663:Furans; D009281:Naphthalenes; D010455:Peptides; D010880:Piperidines; D010975:Platelet Aggregation Inhibitors; C048172:himbacine